Referencias

 
 
  1. Food and Drug Administration. Medical devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails. Jan 2015. Found at: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm431312.pdf
  2. Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs. 1995 Jan;49(1):103-20.
  3. Polak A, Zuag M. Handbook of Experimental Pharmacology vol. 96: Chemotherapy of Fungal Diseases 1990, 504-21.
  4. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination  therapy. J Eur Acad Dermatol Venereol. 2005 Jan;19(1):21-9.
  5. Pittrof F, Gerhards J, Erni W, Klecak G. Loceryl nail lacquer - realization of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol. 1992 Sep;17 Suppl 1:26-8.
  6. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol. 2003 Sep; 149 Suppl 65:1-4.
  7. Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R; European  Onychomycosis Observatory. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol. 2005 Sep; 19 Suppl 1:8-12.
  8. Monod MSecreted proteases from dermatophytes. Mycopathologia. 2008 Nov; 166(5):285-94.
  9. Szepietowski JC, Reich A, Garlowska E, Kulig M, Baran  E, for the Onychomycosis Epidemiology Study GroupFactors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses. Arch Dermatol. 2006; Oct; 142:1279-84.
  10. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998; 11(3):415-29.
  11. Hay RJ, Baron R. Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol. 2011 Dec; 65(6):1219-27
  12. Tosti A, Arenas-Guzmán R. Patients at risk of onychomycosis-risk factor identification and active prevention. J Eur Acad Dermatol Venereol. 2005 Sept;19(S1):13-6.
  13. Baran R, Hay RJ, Garduno JIReview of antifungal therapy and the severity index for assessing onychomycosis: part I. J Dermatolog Treat. 2008 Jan; 19(2):72-81.
  14. Polak A. Amorolfine: A review of its mode of action and in vitro and in vivo antifungal activity. Suppl to J Am Acad Dermatol South-East Asia. 1993 July:11-18.
  15. Loceryl Nail Lacquer 5% - (eMC). Galderma.
  16. Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 Dec; 15(6):489-502.
  17. Polak A, Jäckel A, Noack A, Kappe R.Agar sublimation test for the in vitro determination of the antifungal activity of morpholine derivatives. Mycoses. 2004 Jun; 47(5-6):184-92.
  18. Ghannoum M, Sevin K,  Sarkany M. Amorolfine 5% nail lacquer exhibits potent antifungal activity compared to three acid-based devices indicated for the treatment of onychomycosis: an in vitro nail penetration assay. Dermatology and Therapy. 2015 in press.
  19. Sidou F.  A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers. Int J Tissue React. 2004; 26(1-2):17-24.
  20. Sigurgeirsson B, Olafsson JH, Steinsson JT, Kerrouche N, Sidou F. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol. 2010; 24:910-15.
  21. Yaemsiri S, Hou N, Slining MM, He K. Growth rate of human fingernails and toenails in healthy American young adults. J Eur Acad Dermatol Venereol. 2010; 24(4):420-3.